IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46

Nature Immunology

Volumn 11, Issue 11, 2010, Pages 1030-1038

  Eisenring, Maya ^a   Vom Berg, Johannes ^a   Kristiansen, Glen ^b   Saller, Elisabeth ^a,c   Becher, Burkhard ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c IMD Institut für medizinische and molekulare Diagnostik AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ROR GAMMA T; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; INNATE IMMUNITY; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REJECTION; TUMOR VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; INTERLEUKIN-12; LYMPHOID TISSUE; MELANOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; TUMOR CELLS, CULTURED;

EID: 77958153282     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.1947     Document Type: Article

References (49)

1. Dunn, G.P., Koebel, C.M. & Schreiber, R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6, 836-848 (2006).
2. Kinlen, L.J., Sheil, A.G., Peto, J. & Doll, R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. BMJ 2, 1461-1466 (1979).
3. Buell, J.F., Gross, T.G. & Woodle, E.S. Malignancy after transplantation. Transplantation 80, S254-S264 (2005).
4. Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111 (2001).
5. Dunn, G.P., Old, L.J. & Schreiber, R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360 (2004).
6. Zitvogel, L., Tesniere, A. & Kroemer, G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6, 715-727 (2006).
7. Schoenhaut, D.S. et al. Cloning and expression of murine IL-12. J. Immunol. 148, 3433-3440 (1992).
8. Trinchieri, G. & Sher, A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7, 179-190 (2007).
9. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146 (2003).
10. Nishimura, T. et al. Distinct role of antigen-specifc T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190, 617-627 (1999).
11. Nastala, C.L. et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153, 1697-1706 (1994).
12. Tahara, H. et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54, 182-189 (1994).
13. Noguchi, Y., Jungbluth, A., Richards, E.C. & Old, L.J. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc. Natl. Acad. Sci. USA 93, 11798-11801 (1996).
14. Del Vecchio, M. et al. Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 13, 4677-4685 (2007).
15. Langowski, J.L. et al. IL-23 promotes tumour incidence and growth. Nature 442, 461-465 (2006).
16. Brunda, M.J. et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178, 1223-1230 (1993).
17. Smyth, M.J., Taniguchi, M. & Street, S.E. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J. Immunol. 165, 2665-2670 (2000).
18. Smyth, M.J. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661-668 (2000).
19. Smyth, M.J., Hayakawa, Y., Takeda, K. & Yagita, H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2, 850-861 (2002).
20. Cui, J. et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278, 1623-1626 (1997).
21. Kodama, T. et al. Perforin-dependent NK cell cytotoxicity is suffcient for anti-metastatic effect of IL-12. Eur. J. Immunol. 29, 1390-1396 (1999).
22. Park, S.H., Kyin, T., Bendelac, A. & Carnaud, C. The contribution of NKT cells, NK cells, and other γ-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J. Immunol. 170, 1197-1201 (2003).
23. + cells that provide innate mucosal immune defense. Immunity 29, 958-970 (2008).
24. + cells. Nat. Immunol. 10, 83-91 (2009).
25. + cell populations in gut and skin. Nat. Immunol. 10, 75-82 (2009).
26. + natural killer-like cells. Nat. Immunol. 10, 66-74 (2009).
27. Vivier, E., Spits, H. & Cupedo, T. Interleukin-22-producing innate immune cells: new players in mucosal immunity and tissue repair? Nat. Rev. Immunol. 9, 229-234 (2009).
28. Belladonna, M.L. et al. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J. Immunol. 168, 5448-5454 (2002).
29. Schmidt, S.R. Fusion-proteins as biopharmaceuticals-applications and challenges. Curr. Opin. Drug Discov. Dev. 12, 284-295 (2009).
30. Vosshenrich, C.A. et al. Roles for common cytokine receptor γ-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J. Immunol. 174, 1213-1221 (2005).
31. Beadling, C. & Slifka, M.K. Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27. Arch. Immunol. Ther. Exp. (Warsz.) 54, 15-24 (2006).
32. - inducer cells: evidence that IL-7 signals regulate CD30 ligand but not OX40 ligand expression. J. Immunol. 174, 6686-6691 (2005).
33. Walzer, T. et al. Identifcation, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc. Natl. Acad. Sci. USA 104, 3384-3389 (2007).
34. + cell subsets from Id2-dependent precursors. J. Exp. Med. 207, 273-280 (2009).
35. + lineage distinct from conventional natural killer cells. J. Exp. Med. 207, 281-290 (2010).
36. Mebius, R.E. Organogenesis of lymphoid tissues. Nat. Rev. Immunol. 3, 292-303 (2003).
37. Eberl, G. et al. An essential function for the nuclear receptor RORγ(t) in the generation of fetal lymphoid tissue inducer cells. Nat. Immunol. 5, 64-73 (2004).
38. Takatori, H. et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J. Exp. Med. 206, 35-41 (2009).
39. + lymphoid tissue inducer cells. J. Immunol. 183, 2217-2221 (2009).
40. Ryschich, E., Schmidt, J., Hammerling, G.J., Klar, E. & Ganss, R. Transformation of the microvascular system during multistage tumorigenesis. Int. J. Cancer 97, 719-725 (2002).
41. Buckanovich, R.J. et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 14, 28-36 (2008).
42. Lugade, A.A. et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specifc effector cells that traffc to the tumor. J. Immunol. 174, 7516-7523 (2005).
43. Quezada, S.A. et al. Limited tumor infltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 205, 2125-2138 (2008).
44. Schrama, D. et al. Targeting of lymphotoxin-α to the tumor elicits an effcient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 14, 111-121 (2001).
45. Sun, J.C., Ma, A. & Lanier, L.L. Cutting edge: IL-15-independent NK cell response to mouse cytomegalovirus infection. J. Immunol. 183, 2911-2914 (2009).
46. Shields, J.D., Kourtis, I.C., Tomei, A.A., Roberts, J.M. & Swartz, M.A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328, 749-752 (2010).
47. Marshall, E. Sciencescope. Science 268, 1555 (1995).
48. Daud, A.I. et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol. 26, 5896-5903 (2008).
49. Peggs, K.S., Quezada, S.A., Chambers, C.A., Korman, A.J. & Allison, J.P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206, 1717-1725 (2009).